We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Uramin Inc | LSE:UMN | London | Ordinary Share | VGG9298V1067 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 389.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:4596Y UraMin Inc 15 June 2007 15 June 2007 UraMin Inc. ("UraMin" or the "Company") Uramin notes recent press speculation regarding a transaction for the Company. As the Company remains in negotiations it cannot confirm this speculation and will provide an update to the market as soon as practicable. For further information: Ian Stalker, Chief Executive Officer Tel: +27 (0)11 783 5056 Neil Herbert, Finance Director Tel: +44 (0)11 783 5056 Canaccord Adams Limited Mike Jones Robin Birchall Tyler Broda Tel: +44 (0)20 7518 6500 Financial Dynamics Ben Brewerton Tel: +44 (0)20 7831 3113 Background UraMin (www.uramin.com) was established in 2005 to acquire and develop mineral properties, predominantly uranium. Following the private placement the Company currently has a market capitalization of approximately US$1.9 billion on an undiluted basis. UraMin (www.uramin.com) is traded on the Alternative Investment Market of the London Stock Exchange plc and the Toronto Stock Exchange under the symbol UMN. UraMin is currently focusing on the development of its advanced stage exploration projects at Trekkopje in Namibia, Bakouma in the Central African Republic and Ryst Kuil in South Africa. Through a South African joint venture, UraMin also enjoys additional prospecting license applications for important uranium deposits in the Karoo, South Africa. No assurance can be given that remaining applications for prospecting licences will be successful. Forward-Looking Statements: This press release contains statements that are "forward-looking". Generally, the words "expect," "intend," "estimate," "will" and similar expressions identify forward-looking statements. By their very nature, forward-looking statements are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements, or that of our industry, to differ materially from those expressed or implied in any of our forward-looking statements. Statements in this press release regarding the Company's business or proposed business, which are not historical facts, are "forward looking" statements that involve risks and uncertainties, such as estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. This information is provided by RNS The company news service from the London Stock Exchange END SPCBXGDLBBBGGRU
1 Year Uramin Chart |
1 Month Uramin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions